|
|
Article: Xolair Evaluated in Pediatric Allergic Asthma Study.
- Article from:
- PR Newswire
- Article date:
- May 17, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tanox, Inc. announced that Novartis Pharma A.G., in cooperation with Genentech, Inc., has initiated a Phase III clinical trial of Xolair(R) (omalizumab) in pediatric allergic asthma patients. The pediatric trial is designed as a randomized, double blind, placebo-controlled, and global multi-site study which will enroll approximately 570 patients who are between 6 to 12 years old. The primary objective of the study is to evaluate the efficacy, and safety of Xolair in children with moderate-to-severe, persistent, and inadequately controlled allergic asthma. The duration of the study will be one year. Xolair is being developed under a collaboration agreement among ...